Advancing AAV Therapies From Concept To Commercial Supply

Bringing adeno-associated virus (AAV) therapies to market requires balancing yield, quality, and strict process efficiency. By addressing manufacturability and product quality early in development, therapeutic innovators can significantly mitigate risks. Evaluating critical criteria like identity, purity, and genome integrity prior to scale-up reduces structural liabilities and creates a smoother pathway from gene to clinic.

A robust suspension-based manufacturing platform—utilizing transient transfection of a HEK293 cell line with a triple-plasmid system—simplifies development while maintaining consistent titers across bioreactor formats. Advanced processes support diverse serotypes and novel capsids, delivering strong harvest titers and exceptional process recovery yields up to 70%. Backed by rigorous analytical testing—including deep genomic characterization to verify sequence and inverted terminal repeat (ITR) integrity—this approach optimizes full-capsid enrichment while ensuring absolute regulatory readiness.

Review the complete document to see how these scalable AAV solutions can streamline your clinical development timelines.